Cellectis ADR Dossier
Qualitative Analysis
Business overview
Cellectis S.A. is a clinical-stage biotechnology company pioneering the development of life-saving allogeneic cell and gene therapies. Utilizing its proprietary TALEN® gene-editing platform and PulseAgile electroporation technology, the company is a leader in off-the-shelf cellular immunotherapies. Cellectis is one of the few end-to-end gene-editing companies that controls the entire cell and gene therapy value chain from start to finish, operating state-of-the-art manufacturing facilities in Paris, France, and Raleigh, North Carolina. Its clinical pipeline is anchored by wholly owned candidates targeting hematological malignancies, including lasme-cel (UCART22) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and eti-cel (UCART20x22) for relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lasme-cel (formerly UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) through the pivotal Phase 2 BALLI-01 trial, which was initiated in October 2025.
Expected impact: Transitioning Cellectis into a late-stage development allogeneic CAR-T company and paving the way for a potential Biologics License Application (BLA) filing in 2028.
Developing and optimizing eti-cel (formerly UCART20x22), a highly differentiated allogeneic dual CAR-T targeting both CD20 and CD22, for patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
Expected impact: Maximizing the clinical impact of the dual-target CAR-T candidate in heavily pretreated patients who have relapsed following multiple lines of therapy.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Leverages Cellectis' gene editing expertise and manufacturing capabilities to design and develop up to 10 novel cell and gene therapy candidate products in oncology, immunology, and rare genetic disorders.
Terms: Cellectis received an initial payment of $105 million in Q4 2023 (comprising a $25 million upfront cash payment and an $80 million equity investment). AstraZeneca made an additional $140 million equity investment in May 2024, bringing its total equity stake in Cellectis to approximately 44%. Cellectis is also eligible to receive an IND option fee and development, regulatory, and sales-related milestone payments ranging from $70 million up to $220 million per each of the 10 candidate products, plus tiered royalties.
Sublicensed to Allogene Therapeutics for CD19-directed candidates (such as cema-cel).
Terms: Cellectis is eligible to receive up to $340 million in development and sales milestones, as well as low double-digit royalties on sales.